Session » Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy II: Novel Therapies in Rheumatoid Arthritis - Early in Development

Meeting: 2014 ACR/ARHP Annual Meeting

Abstract Number: 946

Phase 1 Study of Immunotherapy Using Autoantigen-Loaded Dendritic Cells in Patients with Anti-Citrullinated Peptide Antigen Positive Rheumatoid Arthritis

Abstract Number: 947

Efficacy and Safety of NNC01140006, an Anti-IL-21 Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis

Abstract Number: 948

A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate

Abstract Number: 949

Safety and Efficacy of CF101 in Rheumatoid Arthritis Patients: A Phase II Study

Abstract Number: 950

Multiple Mechanisms of Tolerance Characterize the Immune Response to Autologous Modified Dendritic Cells Exposed to Citrullinated Peptides in Patients with Rheumatoid Arthritis

Abstract Number: 951

Safety, Tolerability, and Functional Activity of ABT-122, a Dual TNF- and IL-17A–Targeted DVD-Ig™, Following Single-Dose Administration in Healthy Subjects

« View all sessions from this meeting